XXXX sprayed on gastric mucosa causes @entity4 change.

@entity1 @entity4726 @entity1819 @entity46098 @entity2681 @entity1066 @entity4 @entity356
UNASSIGNED: Background and study aims: @entity46098 (LM), @entity356 , is a safe antispasmodic agent used during esophagogastroduodenoscopy (EGD). However, it seems to affect gastric mucosal endoscopic findings. Therefore, we evaluated whether LM causes specific changes and impacts the endoscopic morphology of @entity1819 . @entity1 and methods: A total of 98 @entity1 scheduled to undergo EGD were randomly assigned to receive LM solution (160mg of 0.8% LM added to 2.5mL of indigo carmine [IC]; n=49; LM group) or decuple-diluted IC solution without LM (n=49; placebo group). We compared the incidence of specific mucosal changes and the difference in the endoscopic findings of several @entity1819 between these groups. Results: Annular-reticular - like mucosal changes appeared immediately after the administration of LM solution. This change was observed in 71.4% of the LM group compared with 12.2% of the placebo group (P<0.01). In the placebo group, this change was observed in 14.7% of subjects with @entity4726 compared with 6.7% of those without @entity4726 (P=0.39), whereas in the LM group, this change was observed in 84.8% of subjects with @entity4726 compared with 43.8% of those without @entity4726 (P<0.01). Most early @entity356 , @entity2681 , and @entity1066 observed in this study became well demarcated after LM administration, although the incidence of @entity1819 did not differ significantly between the two groups. Conclusion: LM changes the gastric mucosa into @entity4 , and this occurs more frequently in @entity356 than in pathologic lesions. LM may facilitate the demarcation of pathologic @entity1819 without intestinal metaplasia.
